Innova Biosciences, the Cambridge UK-based inventor of Lightning-Link® –a world-leading antibody labelling technology – has been awarded a development of prototype grant c£210,000 by the Technology Strategy Board.

GlaxoSmithKline plc (GSK) is buying Cellzome for £61 million cash by hoovering up the shares in the company that it doesn’t already own.

Lab21, the Cambridge UK specialist in personalised medicine, appears to have unlocked a potential commercial goldmine.

Kevin Fitzgerald has stepped down as CEO of antibodies specialist F-star just as the company brings all its research resources into the Cambridge UK bio cluster.

Lab21, a Cambridge UK specialist in personalised medicine and clinical diagnostics, is ramping up operations in the US.

Phytopharm’s share price fell more than eight per cent when the Cambridge UK BiomedTech cluster company reported a disappointing pre-clinical study of its drug Myogane™ in glaucoma.

TAP Biosystems in the Cambridge UK technology cluster is collaborating with scientists at the Open University to produce 3D human CNS tissue models.

Isogenica, a Cambridge UK leader in protein engineering, has secured €700,000 for a new peptide research project.